Clik here to view.
Alvotech and STADA Agree on Strategic Biosimilar Partnership
REYKJAVIK, Iceland & BAD VILBEL, Germany Biopharmaceutical company Alvotech and global pharmaceutical company STADA Arzneimittel AG (“STADA”) today announced that they have entered into an...
View ArticleClik here to view.
Takeda to Highlight Expanded Portfolio of Products Across Oncology and...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) today announced that it will present a total of 29 company-sponsored abstracts at the 61st American...
View ArticleClik here to view.
Ajinomoto and Accenture to Establish Joint Venture to Help Drive Ajinomoto’s...
TOKYO Ajinomoto Co., Inc. and Accenture (NYSE:ACN) have agreed to establish a joint venture in Japan to help the food and biotech company accelerate its operational transformation. The new company,...
View ArticleClik here to view.
Clik here to view.
プロメガがキイトルーダと共用するためのマイクロサテライト不安定性（MSI）コンパニオン診断薬の開発でメルクと世界規模の協業に入る
米ウィスコンシン州マディソン （ビジネスワイヤ） —...
View ArticleClik here to view.
Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”) today announced the randomized, Phase 3 TOURMALINE-MM4 study met its primary endpoint of...
View ArticleClik here to view.
South Korean Company, Yuhan Pharmaceuticals Partners with Cyclica to Advance...
TORONTO & SEOUL, South Korea Renowned South Korean healthcare company, Yuhan Pharmaceuticals (Yuhan) and Cyclica Inc. (Cyclica), a leading neo biotechnology company announce a collaboration to...
View ArticleClik here to view.
武田和MD安德森宣布合作以加快开发临床阶段、开箱即用型CAR NK细胞治疗平台
休斯敦和日本大阪 (美国商业资讯)–德克萨斯大学MD安德森癌症中心(The University of Texas MD Anderson Cancer Center)和武田药品工业株式会社(Takeda Pharmaceutical Company Limited,...
View ArticleClik here to view.
Exelixis’ Collaborator Daiichi Sankyo Announces Positive Results From Phase 3...
ALAMEDA, Calif. Exelixis, Inc. (Nasdaq: EXEL) announced today that its partner Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) has reported positive results from a phase 3 pivotal trial of...
View ArticleClik here to view.
Gynesonics Names Kelly U. Petrucci Vice President of Healthcare Economics and...
REDWOOD CITY, Calif. Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today that medical device...
View ArticleClik here to view.
New Analyses from the Phase 3 HELP Study™ Open-Label Extension in Hereditary...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced new data that further investigates the long-term safety and efficacy of TAKHZYRO® (lanadelumab-flyo)...
View ArticleClik here to view.
武田薬品とMDアンダーソンが臨床試験段階の既製品用CAR NK細胞療法薬プラットフォーム開発を加速するための提携を発表
ヒューストン & 大阪 （ビジネスワイヤ） — テキサス大学MDアンダーソンがんセンターと武田薬品工業株式会社（TSE:4502/NYSE:TAK）（以下、武田薬品）は本日、B細胞性悪性腫瘍やその他のがんの治療に向け、IL-15分泌を促進するとともにキメラ抗原受容体を発現した臍帯血由来ナチュラルキラー（CAR...
View ArticleClik here to view.
Promega与默克达成全球合作，开发可搭配可瑞达®使用的微卫星不稳定(MSI)伴侣诊断试剂
威斯康星州麦迪逊 (美国商业资讯)–Promega Corporation今天宣布与默克（Merck，美国和加拿大以外称为默沙东）达成一项全球合作，开发Promega的微卫星不稳定(MSI)技术作为一种载入说明书的实体瘤伴侣诊断试剂(CDx)，与默克的抗PD-1治疗药物可瑞达®（KEYTRUDA®，帕博利珠单抗）搭配使用。此次全球合作的初期将寻求美国和中国监管部门核准Promega MSI...
View ArticleClik here to view.
Ningbo Tai Kang Medical Technology Co., Ltd Announces Global Licensing...
NINGBO, China Ningbo Tai Kang Medical Technology Co. Ltd. announced today that it has entered into a licensing agreement with AstraZeneca. Tai Kang has been granted the exclusive global rights to...
View ArticleClik here to view.
武田在德国新设的登革热疫苗生产厂揭幕
德国辛根 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE:4502/NYSE:TAK)（“武田”）今天宣布，其登革热候选疫苗TAK-003的新生产厂在德国辛根(Singen)开张。从包装线开始，辛根疫苗厂将用于该登革热候选疫苗的配方、灌装、包装和二次包装。武田在该疫苗厂投资超过1.3亿欧元，并将聘用多达200名员工。...
View ArticleClik here to view.
Clik here to view.
prismCDX Implements Ultivue’s UltiMapper™ Platform for Standardized,...
SEOUL, South Korea prismCDX, a highly specialized contract research organization announced today the selection and adoption of the UltiMapper platform to broaden its offering of translational...
View ArticleClik here to view.
Clik here to view.
Akebia Announces Positive 52-week Efficacy and Safety Data for Vadadustat...
CAMBRIDGE, Mass. Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today...
View ArticleClik here to view.
武田薬品のデング熱ワクチン候補が、デングウイルスの感染歴に関係なく4～16歳の小児・若年層で予防効果を実証
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TSE:4502/NYSE:TAK）（「武田薬品」）は本日、当社のデング熱ワクチン候補（TAK-003）を検討中のピボタル第3相...
View Article